Dr Michael Hall - University of Basel, Switzerland
Dr Michael Hall explains the TOR (target of rapamycin) complex and how this highly conserved, atypical protein kinase plays a large part in cell growth and ageing. TOR controls the overgrowth of cells and is present and over active, in 70-80% of cancer cases. TOR is activated by a number of growth factors, ATP and numerous other catalysts. Dr Hall explains how in this unique case, drugs existed for TOR prior to its discovery and highlights the next generation of TOR inhibitors.
